Esophageal Cancer Clinical Trial

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Summary

This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Age ≥18 and <75 years
Diagnosis of Esophageal cancer or Esophagogastric junction cancer.
Previously received treatment for advanced or metastatic disease.
Measurable disease according to RECIST v1.1.
HLA-A*02 positive
Tumor shows MAGE-A4 expression confirmed by central laboratory.
ECOG Performance Status of 0 or1.
Left ventricular ejection fraction (LVEF) ≥50%.

Note: other protocol defined Inclusion criteria may apply

Key exclusion criteria

Positive for any HLA-A*02 allele other than: one of the inclusion alleles
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study
Active autoimmune or immune mediated disease
Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases
Other prior malignancy that is not considered by the Investigator to be in complete remission. Clinically significant cardiovascular disease
Uncontrolled intercurrent illness
Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus
Pregnant or breastfeeding

Note: other protocol defined Inclusion/Exclusion criteria may apply.

Study is for people with:

Esophageal Cancer

Phase:

Phase 2

Estimated Enrollment:

3

Study ID:

NCT04752358

Recruitment Status:

Terminated

Sponsor:

Adaptimmune

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

City of Hope National Medical Center
Duarte California, 91010, United States
University of Chicago Medicine
Chicago Illinois, 60637, United States
Washington University School of Medicine- Siteman Cancer Center
Saint Louis Missouri, 63110, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
OU Health Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States
Providence Cancer Institute Franz Clinic
Portland Oregon, 97213, United States
University Of Texas, MD Anderson Cancer Center
Houston Texas, 77030, United States
University Of Wisconsin Clinical Science Center
Madison Wisconsin, 53792, United States
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada
McGill University Health Centre Glen Site
Montreal Quebec, H4A 3, Canada
Hospital Universitari Vall d'Hebron
la Vall d'Hebron Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre
Córdoba Madrid, 28041, Spain
Hospital Clinico Universitario de Valencia
Ibáñez Valencia, 46010, Spain
Hospital Fundacion Jimenez Diaz
Madrid , 22804, Spain
Hospital Universitario Madrid Sanchinarro (CIOCC)
Madrid , 28050, Spain
Clinica Universidad de Navarra
Navarro , 31008, Spain
Hospital Universitario Virgen del Rocio
Sevilla , 41013, Spain

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 2

Estimated Enrollment:

3

Study ID:

NCT04752358

Recruitment Status:

Terminated

Sponsor:


Adaptimmune

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.